Effect of sildenafil on IUGR
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20171562Keywords:
AC, Fetal weight, IUGR, SildenafilAbstract
Background: IUGR is one of the major culprit of perinatal mortality and morbidity in India, with reported incidence of 21-28%. Objective of present study is to investigate the effect of sildenafil on pregnancies complicated with IUGR and to see its effect on fetal outcome.
Methods: This was a case control study conducted after clearance of Ethical Committee of the Institute from July 2014 to July 2016 in Department of Obstetrics and Gynecology of Dr. B.R.A.M. Hospital, Raipur [C.G.]. All women with pregnancies complicated with IUGR were identified and included in study. According to treatment with Sildenafil women were divided in two groups. Both groups were followed up till delivery and their outcome including birth weight, AC and complications related to IUGR were compared.
Results: IUGR was found to be more prevalent in primi gravidas and women of lower socioeconomic and educational status with low BMI. We found Hypertension in pregnancy as significant causative factor precipitating the IUGR [68%]. In sildenafil treated group significant 63% mothers had baby with birth weight >10 percentile whereas in sildenafil non treated group only 20% had > 10 percentile birth weight. The mean birth weight of Sildenafil treated group was 2594gm whereas in non-treated group it was 2200gm. In our study, we observed improved AC in 70% whereas in control group improvement was only in 34% which was significant.
Conclusions: Sildenafil was found to improves birth weight, abdominal circumference, and reduce the complications related to IUGR.
Metrics
References
Murki S, Sharma D. Intrauterine growth retardation: A review article. J Neonatal Biol. 2014;3:135.
Saleem T, Sajjad N, Fatima S, Habib N, Ali SR, Qadir M. Intrauterine growth retardation-small events, big consequences. Ital J Paediatr. 2011;37:41.
Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in antenatal surveillance, diagnosis, and management. AJOG. 2011;204(4):288-300.
Militello M, Pappalardo EM, Ermito S. Angela Diantale Alessandro Cavaliere and Sabina Carrara Obstetric management of IUGR. J Prenatal Medic. 2009;3(1):6-9.
Srinivas SK, Edlow AG, Nelf PM, Sammel MD, Andrela CM, Elovitz MA. Rethinking IUGR in pre-eclampsia; dependent or independent of maternal hypertension. J Perinatol. 2009;29(10):680-4.
Zafar H, Naz M, Fatima U, Irshad F. Frequency of IUGR in pregnancy induced hypertension. JUMDC. 2012;3(2):8-13.
Samangaya RA, Mires G, Shennan A, Skillen L, Howe D, Mc Leod A, Baker P.N. A randomized double blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor Sildenafil for the treatment of pre eclampsia. Hypertens pregnancy. 2009;28:369-82.
von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG. 2011 Apr;118(5):624-8.
Dastjerdi MV, Hosseini S, Bayani L. Sildenafil citrate and uteroplacental perfusion in fetal growth restriction. J Res Med Sci. 2012;17(7):632-6.
Ganzevoort W, Alfirevic Z, von Dadelszen P, Kenny L, Papageorghiou A, van Wassenaer-Leemhuis A, et al. STRIDER: sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction-a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014;3:23.
Jacobsen JCGC. The necessity of randomized clinical trials. Br J Med Med Res. 2013;3(4);16.
Downloads
Published
How to Cite
Issue
Section
